Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Y-mAbs Therapeutics Inc YMAB

Healthcare Biotechnology
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product... see more

Recent & Breaking News (NDAQ:YMAB)

Y-mAbs to Host Virtual Research & Development Day on Wednesday, December 16

GlobeNewswire December 7, 2020

Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel

GlobeNewswire December 4, 2020

FDA Approves Y-mAbs' DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma

GlobeNewswire November 25, 2020

Y-mAbs Announces Update on Omburtamab in DIPG

GlobeNewswire November 19, 2020

Y-mAbs Announces Third Quarter 2020 Financial Results and Recent Corporate Developments

GlobeNewswire November 5, 2020

Y-mAbs to Announce Third Quarter 2020 Financial and Operating Results on November 5, 2020

GlobeNewswire October 29, 2020

Y-mAbs Announces FDA Clearance of IND for Lutetium-177 Labeled Omburtamab Antibody for Adult Indications

GlobeNewswire October 26, 2020

Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma

GlobeNewswire October 16, 2020

Y-mAbs Announces FDA Clearance of IND for its Lutetium-177 Labeled Omburtamab Antibody

GlobeNewswire October 14, 2020

Bragar Eagel & Squire, P.C. Is Investigating Evolus, Lizhi, Iovance Biotherapeutics, and Y-mAbs Therapeutics and Encourages Investors to Contact the Firm

GlobeNewswire October 9, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB

PR Newswire October 8, 2020

Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Y-mAbs Therapeutics, Inc. (YMAB) Investigation

ACCESSWIRE IA October 8, 2020

Y-mAbs' Nivatrotamab for the Treatment of Patients with Neuroblastoma Granted Orphan Drug Designation and Rare Pediatric Disease Designation by FDA

GlobeNewswire October 7, 2020

Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma

GlobeNewswire October 5, 2020

Y-mAbs Announces Second Quarter 2020 Financial Results and Recent Corporate Developments

GlobeNewswire August 6, 2020

Y-mAbs Announces Completion of Submission of Omburtamab Biologics License Application to FDA

GlobeNewswire August 6, 2020

Y-mAbs to Announce Second Quarter 2020 Financial and Operating Results on August 6, 2020

GlobeNewswire August 4, 2020

Y-mAbs Announces Data to be Presented at 2020 SIOP

GlobeNewswire July 27, 2020

Y-mAbs Announces Update on SADA Technology and New Preclinical SADA Construct

GlobeNewswire July 14, 2020

Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA

GlobeNewswire June 30, 2020